

**Amendments to the Claims:**


This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-11 are amended.

**Listing of Claims:**

1. (Currently Amended) Thioxylose compounds, ~~characterized in that they~~ wherein the compounds are selected from:

a) the compounds of the formula



in which:

– the pentapyranosyl group is a 5-thio-β-D-xylopyranosyl group or a 5-thio-β-L-xylopyranosyl group,

– R is a hydrogen atom, a C<sub>2</sub>-C<sub>6</sub> acyl group, an acetyl group substituted by a nitrogen heterocycle, or a group -COOR',

– R<sub>1</sub> and R<sub>2</sub> independently of one another are each a hydrogen atom, a halogen atom, a cyano, nitro or trifluoromethyl group, a C<sub>1</sub>-C<sub>4</sub> alkyl group optionally substituted by an aromatic ring, a group -COOR', a group -CH<sub>2</sub>-NR'R'', a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a group -NH-CO-R' or a group -NH-SO<sub>2</sub>-R', and

– R' and R'' independently are each a C<sub>1</sub>-C<sub>4</sub> alkyl group; and

b) their addition salts, oxides or quaternary ammonium salts.

2. (Currently Amended) Compound according to claim 1, ~~characterized in that~~ wherein the pentapyranosyl group is a 5-thio-β-D-xylopyranosyl group or a 5-thio-β-L-xylopyranosyl group,

R is a hydrogen atom, a C<sub>2</sub>-C<sub>6</sub> acyl group or a group -COOR',

R' is a C<sub>1</sub>-C<sub>3</sub> alkyl group, and

R<sub>1</sub> and R<sub>2</sub> independently of one another are each a hydrogen atom, a halogen atom, a cyano, nitro or trifluoromethyl group or a C<sub>1</sub>-C<sub>4</sub> alkyl group optionally substituted by an aromatic ring.

3. (Currently Amended) Compound according to ~~claim 1 or 2, characterized in that~~ claim 1, wherein the pentapyranosyl group is the 5-thio-β-D-xylopyranosyl group.

4. (Currently Amended) Compound according to ~~any one of claims 1 to 3, characterized in that~~ claim 1, wherein the pentapyranosyl group is in the 3-position of the pyridine heterocycle.


5. (Currently Amended) Compound according to ~~any one of claims 1 to 4, characterized in that~~ claim 1, wherein R<sub>1</sub> and R<sub>2</sub> are a hydrogen atom.

6. (Currently Amended) Compound according to ~~one of claims 1 to 5, characterized in that~~ claim 1, wherein R is a hydrogen atom.

7. (Currently Amended) Compound according to ~~one of claims 1 to 5, characterized in that~~ claim 1, wherein R is a group -COCH<sub>3</sub>, a group -COOCH<sub>3</sub> or a group -COOC<sub>2</sub>H<sub>5</sub>.

8. (Currently Amended) Process for the manufacture of a compound according to ~~any one of claims 1 to 7, characterized in that it comprises steps consisting in~~ claim 1, wherein the process comprises:


a) reacting a pyridinol of the formula




in which:

– R<sub>1</sub> and R<sub>2</sub> independently of one another are each a hydrogen atom, a halogen atom, a cyano, nitro or trifluoromethyl group, a C<sub>1</sub>-C<sub>4</sub> alkyl group optionally substituted by an aromatic ring, a group -COOR', a group -CH<sub>2</sub>-NR'R'', a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a group -NH-CO-R' or a group -NH-SO<sub>2</sub>-R', and

– R' and R'' independently are each a C<sub>1</sub>-C<sub>4</sub> alkyl group,  
with a 5-thioxypyranose derivative of the formula




in which Hal is a halogen, preferably bromine, and R is a C<sub>2</sub>-C<sub>6</sub> acyl group, in an aprotic solvent, in the presence of a silver salt or a zinc salt, in an anhydrous medium, at a temperature of between 25 and 80°C, for 1 to 10 hours, to give the compound of formula I or the corresponding N-oxide:



in which the pentapyranose group is D- or L-5-thioxypyranose and R, R<sub>1</sub> and R<sub>2</sub> are as defined in the starting compounds;

b) if necessary, reacting the compound of formula I obtained above with a solution of ammonia in methanol to give the compound of the formula




in which  $R_1$  and  $R_2$  are as defined above; and

c) if necessary, reacting one of the compounds obtained above, I or Ia, with an acid to give the corresponding addition salt; or


d) if necessary, reacting one of the compounds obtained above, of formula I or Ia, with an organic halide to give the corresponding ammonium salt.

9. (Currently Amended) Process for the manufacture of a compound according to ~~any one of claims 1 to 7, characterized in that it comprises steps consisting in~~ claim 1, wherein the process comprises:

a) reacting the tetra-O-acetyl-5-thioxopyranose of the formula:



in which Ac is the acetyl group, with a compound of the formula




in which:

–  $R_1$  and  $R_2$  independently of one another are each a hydrogen atom, a halogen atom, a cyano, nitro or trifluoromethyl group, a  $C_1$ - $C_4$  alkyl group optionally substituted by an aromatic ring, a group  $-COOR'$ , a group  $-CH_2-NR'R''$ , a  $C_1$ - $C_4$  alkoxy group, a group  $-NH-CO-R'$  or a group  $-NH-SO_2-R'$ , and


–  $R'$  and  $R''$  independently are each a  $C_1$ - $C_4$  alkyl group,

in an aprotic solvent, in the presence of a catalyst of the Lewis acid type, at a temperature of between 20 and 60°C, for 1 to 2 hours, to give the compound of the formula



in which R<sub>1</sub> and R<sub>2</sub> are as defined in the starting compounds;

b) if necessary, reacting the compound of formula I obtained above with sodium methylate in methanol to give the compound of the formula



in which R<sub>1</sub> and R<sub>2</sub> are as defined above; and

c) if necessary, reacting one of the compounds obtained above, I or Ia, with an acid to give the corresponding addition salt.

10. (Currently Amended) Compound according to ~~any one of claims 1 to 7 for its use as a drug~~ claim 1, wherein the compound is a drug.

11. (Currently Amended) ~~Use of a~~ A compound according to ~~any one of claims 1 to 7~~ claim 1, wherein the compound is utilized for the preparation of a drug intended for the prevention or treatment of thromboses, especially venous thromboses.